Phase 1 Trial Update
Single ascending doses tested so-far
• Well tolerated
• No safety concerns so-far
• Showing excellent pharmaceutic properties
• Multiple ascending dose expected to start soon
• On track to complete dosing in Q2 2021
Well tolerated, no safety concerns, showing excellent pharmaceutical properties.
We are certainly on the right track ... so far so good
Excellent ...
.
Ann: Investor Update - February 2021, page-3
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.97M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 12.0¢ | $8.355K | 68.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20761 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 155906 | 2 |
View Market Depth
| Last trade - 15.44pm 29/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |